The test, named EvoScore START, measures a panel of blood-based protein biomarkers to distinguish between epileptic seizures and other similar events.
The cell lines were edited with CRISPR/Cas9 to create fusions of GFP with the proteins of interest, allowing researchers to image structures in real time.
The researchers added that these expression changes could be used to predict when a bloom might occur.
The company said it will use the funds to commercialize its proteomic PromarkerD kidney disease test and launch an analytical testing service business.
The exclusive agreement covers a portfolio of Epicentre products for transposomics, microarray analysis, and transcriptomics research.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.